Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marta Benavent Viñuales
Observed names:
M. Benavent Viñuales,
Marta Benavent
Institutions:
Instituto de Biomedicina de Sevilla,
Hospital Universitario Virgen del Rocío
Observed institutions:
Instituto de Biomedicina de Sevilla,
Hospital Universitario Virgen del Rocío,
GEICAM – Spanish Breast Cancer Group,
Universidad de Sevilla
ORCID:
0000-0003-1268-4588
Observed ORCID:
0000-0003-1268-4588
OpenAlex ID:
A5090908737
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
2025
·
Jaume Capdevila
, Virginia Pubul
, et al.
·
BMC Cancer
·
18
PDF
723O Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multi-cohort basket phase II trial (CABATEN/GETNE-T1914)
2023
·
J. Capdevila Castillon
, J. Molina-Cerrillo
, et al.
·
Annals of Oncology
·
14
PDF
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)
2025
·
Jaume Capdevila
, Jorge Hernando
, et al.
·
Clinical Cancer Research
·
13
Cabozantinib plus atezolizumab in locally advanced/metastatic adrenocortical carcinoma: Results from a multi-cohort basket phase II trial, CABATEN/GETNE-T1914.
2024
·
Enrique Grande
, Marta Benavent Viñuales
, et al.
·
Journal of Clinical Oncology
·
10
Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
2013
·
Rodrigo Dienstmann
, Josep Tabernero
, et al.
·
Journal of Clinical Oncology
·
9
1098O Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)
2021
·
M.C. Riesco-Martinez
, J. Capdevila
, et al.
·
Annals of Oncology
·
7
PDF
Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study
2024
·
Virginia Lope
, Ángel Guerrero-Zotano
, et al.
·
The journal of nutrition health & aging
·
6
1142O Multivariable analysis of streptozotocin plus 5-fluorouracil and everolimus sequences in advanced pancreatic neuroendocrine tumor patients: The SEQTOR trial (GETNE-1206)
2024
·
J. Capdevila Castillon
, S. Tafuto
, et al.
·
Annals of Oncology
·
4
PDF
177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial.
2024
·
Alejandro Garcia-Alvarez
, Rocio Garcia-Carbonero
, et al.
·
Journal of Clinical Oncology
·
4
PDF
Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914).
2024
·
Jorge Hernando
, Javier Molina-Cerrillo
, et al.
·
Journal of Clinical Oncology
·
4
575TiP Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
2021
·
E. Grande
, R. Garcia-Carbonero
, et al.
·
Annals of Oncology
·
3
1107P Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
2021
·
J. Capdevila
, S. Landolfi
, et al.
·
Annals of Oncology
·
3
Assessment of Prognostic and Therapeutic Factors in Male Breast Cancer: An Observational Study of a Southwest Spanish Single Center
2020
·
Daniel Herrero
, María Rocío Morales Herrero
, et al.
·
Archives of Breast Cancer
·
3
PDF
Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.
2014
·
Guillem Argilés
, Rodrigo Dienstmann
, et al.
·
Journal of Clinical Oncology
·
3
A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.
2016
·
Enrique Grande
, Daniel E. Castellano
, et al.
·
Journal of Clinical Oncology
·
2
Data from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)
2025
·
Jaume Capdevila
, Jorge Hernando
, et al.
·
1
1144O Osteopontin (OPN) predicts the efficacy of anti-angiogenic therapy with multikinase inhibitors (MKIs) in advanced neuroendocrine tumors (NETs): Underlying molecular mechanisms
2024
·
A. Lens-Pardo
, C. Carretero-Puche
, et al.
·
Annals of Oncology
·
1
PDF
Unveiling the relationship between the UGT2B gene family and neoadjuvant treatment response in patients with HER2-positive breast cancer.
2024
·
Ana Gil
, M Ángeles Dominguez-Cejudo
, et al.
·
Journal of Clinical Oncology
·
1
Circulating LncRNAs as predictive biomarkers by molecular subtypes in advanced breast tumors.
2017
·
Javier Salvador
, Maria Luisa Pecero
, et al.
·
Journal of Clinical Oncology
·
1
Review of Haematological Toxicities in Well-Differentiated Neuroendocrine Tumours: A Case Report and Comprehensive Review of the Literature
2026
·
David Gomez
, Ramón Salazar
, et al.
·
Journal of Clinical Medicine
PDF
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
2026
·
Jaume Capdevila
, Virginia Pubul
, et al.
·
BMC Cancer
PDF
Supplementary Data1 from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)
2025
·
Jaume Capdevila
, Jorge Hernando
, et al.
PDF
Study protocol1 from Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)
2025
·
Jaume Capdevila
, Jorge Hernando
, et al.
PDF
388P Impact of prior therapy and hormone resistance on everolimus-exemestane efficacy in the post-CDK4/6 inhibitor era: A real-world study
2025
·
P. Delgado Garces
, M. Benavent Viñuales
, et al.
·
ESMO Open
PDF
1143O Refining molecular classification of neuroendocrine tumors from diverse origins using multi-omic integration models: Unveiling novel neuroendocrine subtypes and their clinical implications
2024
·
C. Carretero-Puche
, B. Antón Pascual
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
29
Citation count:
107
H-index:
6
I10-index:
4
Year
Topic
Type